| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
|
Joerger, M.
|
|
|
22 |
3 |
p. 567-574
|
artikel
|
| 2 |
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
|
Heinemann, V.
|
|
|
22 |
3 |
p. 603-608
|
artikel
|
| 3 |
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin–docetaxel, plus radical concurrent chemoradiotherapy with cisplatin–docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer
|
Senan, S.
|
|
|
22 |
3 |
p. 553-558
|
artikel
|
| 4 |
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
|
Schneeweiss, A.
|
|
|
22 |
3 |
p. 609-617
|
artikel
|
| 5 |
Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region
|
Lam, E.K.K.
|
|
|
22 |
3 |
p. 730-738
|
artikel
|
| 6 |
Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study
|
Merlano, M.
|
|
|
22 |
3 |
p. 712-717
|
artikel
|
| 7 |
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
|
Conconi, A.
|
|
|
22 |
3 |
p. 689-695
|
artikel
|
| 8 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
|
Metro, G.
|
|
|
22 |
3 |
p. 625-630
|
artikel
|
| 9 |
Coffee and cancers of the upper digestive and respiratory tracts: meta-analyses of observational studies
|
Turati, F.
|
|
|
22 |
3 |
p. 536-544
|
artikel
|
| 10 |
Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma
|
Ngeow, J.
|
|
|
22 |
3 |
p. 718-722
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
22 |
3 |
p. ii-iii
|
artikel
|
| 12 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer
|
Dahabreh, I.J.
|
|
|
22 |
3 |
p. 545-552
|
artikel
|
| 13 |
ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
|
Besse, B.
|
|
|
22 |
3 |
p. 575-581
|
artikel
|
| 14 |
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
|
Barrington, S.F.
|
|
|
22 |
3 |
p. 739-745
|
artikel
|
| 15 |
Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet
|
Kamo, N.
|
|
|
22 |
3 |
p. 723-729
|
artikel
|
| 16 |
18F-fluorodeoxyglucose–positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
|
Cahu, X.
|
|
|
22 |
3 |
p. 705-711
|
artikel
|
| 17 |
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
|
Smith, I.E.
|
|
|
22 |
3 |
p. 595-602
|
artikel
|
| 18 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging
|
Dingemans, A.-M. C.
|
|
|
22 |
3 |
p. 559-566
|
artikel
|
| 19 |
Free mobility of medical oncologists across the European Union: still a false myth
|
Schiavon, G.
|
|
|
22 |
3 |
p. 746-747
|
artikel
|
| 20 |
Fused FDG–PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen
|
Picardi, M.
|
|
|
22 |
3 |
p. 671-680
|
artikel
|
| 21 |
How to follow up advanced-stage borderline tumours? Mode of diagnosis of recurrence in a large series stage II–III serous borderline tumours of the ovary
|
Uzan, C.
|
|
|
22 |
3 |
p. 631-635
|
artikel
|
| 22 |
Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis
|
Scholz, M.
|
|
|
22 |
3 |
p. 681-688
|
artikel
|
| 23 |
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
|
Potthoff, K.
|
|
|
22 |
3 |
p. 524-535
|
artikel
|
| 24 |
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
|
Dawood, S.
|
|
|
22 |
3 |
p. 515-523
|
artikel
|
| 25 |
Is FISH floating or still swimming in the lung cancer ocean?
|
Cappuzzo, F.
|
|
|
22 |
3 |
p. 493-499
|
artikel
|
| 26 |
Is the Ki-67 labelling index ready for clinical use?
|
Jonat, W.
|
|
|
22 |
3 |
p. 500-502
|
artikel
|
| 27 |
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer
|
Wildiers, H.
|
|
|
22 |
3 |
p. 588-594
|
artikel
|
| 28 |
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy
|
Johannsen, M.
|
|
|
22 |
3 |
p. 657-663
|
artikel
|
| 29 |
Predictors of state-of-the-art management of early breast cancer in Switzerland
|
Ess, S.
|
|
|
22 |
3 |
p. 618-624
|
artikel
|
| 30 |
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
|
Rieger, M.
|
|
|
22 |
3 |
p. 664-670
|
artikel
|
| 31 |
Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
|
Minig, L.
|
|
|
22 |
3 |
p. 643-649
|
artikel
|
| 32 |
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
|
DeCensi, A.
|
|
|
22 |
3 |
p. 582-587
|
artikel
|
| 33 |
Prospective study on the FDG–PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer
|
Martoni, A.A.
|
|
|
22 |
3 |
p. 650-656
|
artikel
|
| 34 |
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)
|
Nomura, H.
|
|
|
22 |
3 |
p. 636-642
|
artikel
|
| 35 |
Reply to Should diagnostic laparoscopy be conducted before hormonal treatment in early-stage endometrial cancer?
|
Sideri, M.
|
|
|
22 |
3 |
p. 749
|
artikel
|
| 36 |
Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information
|
Chou, W.-C.
|
|
|
22 |
3 |
p. 696-704
|
artikel
|
| 37 |
Should diagnostic laparoscopy be conducted before hormonal treatment in early-stage endometrial cancer?
|
Jung, Y.W.
|
|
|
22 |
3 |
p. 748-749
|
artikel
|
| 38 |
Table of Contents
|
|
|
|
22 |
3 |
p. iv-vi
|
artikel
|
| 39 |
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
|
Lønning, P.E.
|
|
|
22 |
3 |
p. 503-514
|
artikel
|
| 40 |
Treatment of cancer with drugs: a controversy
|
Guedea, F.
|
|
|
22 |
3 |
p. 747-748
|
artikel
|
Tijdschrift beschrijving